Infective endocarditis and solid organ transplantation: Only worse outcomes during initial transplantation hospitalization - 26/09/21
, Jerome J. Federspiel, MD, PhD c, dRésumé |
Background |
The epidemiology, and outcome of infective endocarditis (IE) among solid organ transplant (SOT) recipients is unknown.
Methods |
We used data from the 2013-2018 Nationwide Readmissions Database (NRD). IE- and SOT-associated hospitalizations were identified using diagnosis and procedure codes. Outcomes included inpatient mortality, length of stay, and inpatient costs. Adjusted analyses were performed using weighted regression models.
Results |
A total of 99,052 IE-associated hospitalizations, corresponding to a weighted national estimate of 193,164, were included for analysis. Of these, 794 (weighted n = 1,574) were associated with transplant history (SOT-IE). Mortality was not significantly different between SOT-IE and non-SOT-IE (17.2% vs. 15.8%, adjusted relative risk [aRR]: 0.86, 95% confidence interval [CI] [0.71, 1.03]), and fewer SOT-IE patients underwent valve repair or replacement than non-SOT-IE (12.5% vs. 16.2%, aRR 0.82, 95% CI [0.71, 0.95]). We then compared outcomes of patients diagnosed with IE during their index transplant hospitalization (index-SOT-IE) to patients without IE during their transplant hospitalization (index-SOT). Index-SOT-IE occurred most frequently among heart transplant recipients (45.1%), and was associated with greater mortality (27.1% vs. 2.3%, aRR 6.07, 95% CI [3.32, 11.11]).
Conclusion |
Dual diagnosis of SOT and IE was associated with worse outcomes among SOT recipients during index hospitalization, but not overall among patients with IE.
Le texte complet de cet article est disponible en PDF.Plan
Vol 240
P. 63-72 - octobre 2021 Retour au numéro
Article précédent
- Renin–angiotensin–aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system
- Alexander T Sandhu, Shun Kohsaka, Shoutzu Lin, Christopher Y Woo, Mary K. Goldstein, Paul A Heidenreich
- Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials
- Gad Cotter, Beth A. Davison, Christopher Edwards, Stefanie Senger, John R. Teerlink, Faiez Zannad, Olav Wendelboe Nielsen, Marco Metra, Alexandre Mebazaa, Ovidiu Chioncel, Barry H Greenberg, Aldo P Maggioni, Georg Ertl, Naoki Sato, Alain Cohen-Solal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?